307 related articles for article (PubMed ID: 36383911)
21. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Senter PD; Sievers EL
Nat Biotechnol; 2012 Jul; 30(7):631-7. PubMed ID: 22781692
[TBL] [Abstract][Full Text] [Related]
22. Antibody-Drug Conjugates in Myeloid Leukemias.
Senapati J; Daver NG; Pemmaraju N
Cancer J; 2022 Nov-Dec 01; 28(6):454-461. PubMed ID: 36383908
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed/Refractory Lymphomas.
Hashmi H; Darwin A; Nishihori T
Hematol Oncol Stem Cell Ther; 2023 Jan; 16(1):21-34. PubMed ID: 36634275
[TBL] [Abstract][Full Text] [Related]
24. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Ricart AD
Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD30 Antibodies for Hodgkin lymphoma.
Foyil KV; Bartlett NL
Curr Hematol Malig Rep; 2010 Jul; 5(3):140-7. PubMed ID: 20446121
[TBL] [Abstract][Full Text] [Related]
26. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
27. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
Amaya ML; Jimeno A; Kamdar M
Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823
[TBL] [Abstract][Full Text] [Related]
28. A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS).
Tang L; Sun C; Liu W; Wu H; Ding C
Front Pharmacol; 2024; 15():1362484. PubMed ID: 38384285
[No Abstract] [Full Text] [Related]
29. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads.
Chia CSB
ChemMedChem; 2022 Jun; 17(11):e202200032. PubMed ID: 35384350
[TBL] [Abstract][Full Text] [Related]
30. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.
Bourbon E; Salles G
Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972
[TBL] [Abstract][Full Text] [Related]
31. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
32. ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma.
Alderuccio JP; Sharman JP
Blood Rev; 2022 Nov; 56():100967. PubMed ID: 35489963
[TBL] [Abstract][Full Text] [Related]
33. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.
Robak T; Robak E
Expert Opin Investig Drugs; 2014 Jul; 23(7):911-24. PubMed ID: 24708159
[TBL] [Abstract][Full Text] [Related]
34. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
35. Drug-conjugated antibodies for the treatment of cancer.
Lambert JM
Br J Clin Pharmacol; 2013 Aug; 76(2):248-62. PubMed ID: 23173552
[TBL] [Abstract][Full Text] [Related]
36. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
Bradley AM; Devine M; DeRemer D
Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511
[TBL] [Abstract][Full Text] [Related]
37. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Aujla A; Aujla R; Liu D
Biomark Res; 2019; 7():9. PubMed ID: 31011424
[TBL] [Abstract][Full Text] [Related]
38. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
39. Antibody-drug conjugates--an emerging class of cancer treatment.
Diamantis N; Banerji U
Br J Cancer; 2016 Feb; 114(4):362-7. PubMed ID: 26742008
[TBL] [Abstract][Full Text] [Related]
40. An Anti-CD22-
Yu SF; Lee DW; Zheng B; Del Rosario G; Leipold D; Booler H; Zhong F; Carrasco-Triguero M; Hong K; Yan P; Rowntree RK; Schutten MM; Pillow T; Sadowsky JD; Dragovich PS; Polson AG
Mol Cancer Ther; 2021 Feb; 20(2):340-346. PubMed ID: 33273056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]